Prevention and management of transplant-associated diabetes

Bibliography

• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization; 1999
   Google Scholar
• Davidson J, Wilkinson A, Dantal J, New-Onset Diabetes after Transplantation: 2003 international consensus guidelines. Transplantation 2003;75(Suppl):SS3-SS24
   Google Scholar
• Wilkinson A, Davidson J, Dotta F, Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291-8
   PubMed Web of Science ®Google Scholar
• Cosio FG, Kudva Y, van der Velde M, New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-21
   PubMed Web of Science ®Google Scholar
• Valderhaug TG, Hjelmesæth J, Hartmann A, The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011;54:1341-9
   Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85
   PubMed Web of Science ®Google Scholar
• Hjelmesæth J, Hartmann A, Leivestad T, The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006;69:588-95
   PubMed Web of Science ®Google Scholar
• Cole EH, Johnston O, Rose CL, Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-21
   PubMed Web of Science ®Google Scholar
• Matas AJ, Wilkinson A, Dantal J, Posttransplant diabetes mellitus and acute rejection: Impact on kidney transplant outcome. Transplantation 2008;85:338-43
   Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):S62-9
   PubMed Web of Science ®Google Scholar
• Selvaraj N, Boddy Z, Sridhar MG. Increased glycation of hemoglobin in chronic renal failure: (Corrected) potential role of oxidative stress. Arch Med Res 2008;39:277-84; published erratum appears in Arch Med Res 2008;39:466
   PubMed Web of Science ®Google Scholar
• De Marchi S, Cecchin E, Basile A, More on the increase of hemoglobin A1c in chronic renal failure: the role of acidosis. Nephron 1983;35:49-53
   Google Scholar
• Hornum M, Jørgensen KA, Hansen JM, New-onset diabetes mellitus after kidney transplantation in Denmark. Clin Am J Soc Nephrol 2010;5:709-16
   PubMed Web of Science ®Google Scholar
• Hagen M, Hjelmesæth J, Jenssen T, A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant patients. Nephrol Dial Transplant 2003;18:2154-9
   PubMed Web of Science ®Google Scholar
• Montori VM, Velosa JA, Basu A, Post-transplant diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-92
   PubMed Web of Science ®Google Scholar
• Baid S, Cosimi AB, Farrell ML, Post-transplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-72
   PubMed Web of Science ®Google Scholar
• Knobler H, Stagnaro-Green A, Wallenstein S, Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30-3
   PubMed Web of Science ®Google Scholar
• Hjelmesæth J, Hartmann A, Kofstad J, Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-83
   PubMed Web of Science ®Google Scholar
• Valderhaug TG, Hjelmeæsth J, Rollag H, Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007;84:1125-30
   Web of Science ®Google Scholar
• Cosio FG, Pesavento TE, Osei K, Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-7
   PubMed Web of Science ®Google Scholar
• Hertz MI, Taylor DO, Trulock EP, The registry of the International Society for Heart and Lung Transplantation: nineteenth official report. J Heart Lung Transplant 2002;21:950-70
   PubMed Web of Science ®Google Scholar
• Silverborn M, Jeppsson A, Martensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005;24:1536-43
   Google Scholar
• Soule JL, Olyaei AJ, Boslaugh TA, Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. Am J Surg 2005;189:552-7
   Google Scholar
• Ducluox D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005;79:438-43
   Google Scholar
• Kuo HT, Sampaio MS, Vincenti F, Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: An analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (PPTN/UNOS) database. Am J Kidney Dis 2010;56:1127-39
   PubMed Web of Science ®Google Scholar
• Hjelmesæth J, Hagen M, Hartmann A, The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002;16:389-96
   PubMed Web of Science ®Google Scholar
• Hjelmesæth J, Jenssen T, Midtvedt K, Insulin resistance after renal transplantation. Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001;24:2121-6
   Google Scholar
• Hur KY, Nam CM, Kim MS, Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007;30:609-15
   PubMed Web of Science ®Google Scholar
• Vincenti F, Friman S, Scheuermann E, Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14
   PubMed Web of Science ®Google Scholar
• Khalili M, Lim JW, Bass N, New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004;10:349-55
   PubMed Web of Science ®Google Scholar
• Driscoll C, Cashion A, Hathaway DK, Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006;16:110-16
   Google Scholar
• Martinez-Dolz L, Almenar L, Martinez-Ortis L, Predictive factors for development of diabetes mellitus post-heart transplant. Transplant Proc 2005;37:4064-6
   Google Scholar
• Depczynski B, Daly B, Campbell LV, Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 2000;17:15-19
   Google Scholar
• Saliba F, Lakehal M, Pageaux GP, Risk factor for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007;13:136-44
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Dixit V, Post-transplant diabetes mellitus and HCV sero-positive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant 2005;5:2433-40
   PubMed Web of Science ®Google Scholar
• Hjelmesæth J, Muller F, Jenssen T, Asymptomatic cytomegalus virus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550-6
   PubMed Web of Science ®Google Scholar
• Aasebø W, Midtvedt K, Valderhaug TG, Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010;25:1289-93
   PubMed Web of Science ®Google Scholar
• Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96:513-23
   PubMed Web of Science ®Google Scholar
• Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
   PubMed Web of Science ®Google Scholar
• Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997;99:414-23
   PubMed Web of Science ®Google Scholar
• Delaunay F, Khan A, Cintra A, Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094-8
   PubMed Web of Science ®Google Scholar
• Burroughs TE, Lentine KL, Takemoto SK, Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007;2:517-23
   PubMedGoogle Scholar
• Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010;90:343-9
   PubMed Web of Science ®Google Scholar
• Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010;89:1-14
   PubMed Web of Science ®Google Scholar
• Woodle ES, First MR, Pirsch J, A prospective, randomized, double-blind, placebo-controlled trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564-77
   PubMed Web of Science ®Google Scholar
• Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011;91:334-41
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Hjelmesæth J, Hartmann A, Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15:3233-9
   PubMed Web of Science ®Google Scholar
• Vitko S, Klinger M, Salmela K, Two cortico-steroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005;80:1734-41
   PubMed Web of Science ®Google Scholar
• Bergrem HA, Bergrem H, Hartmann A, Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation. Ther Drug Monit 2008;30:583-90
   Google Scholar
• Laftavi MR, Staphan R, Stefanick B, Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005;137:364-71
   PubMed Web of Science ®Google Scholar
• Stillman IE, English J, Burdmann EA, Prednisone alters the histopathology of chronic cyclosporine nephropathy. Exp Nephrol 1997;5:61-8
   Google Scholar
• Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;31:1-13
   Google Scholar
• Van Duijnhoven AM, Christiaans MHL, Boots HMM, Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13:213-20
   PubMed Web of Science ®Google Scholar
• Margreiter R; for the European Tacrolimus vs. Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosorin microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002;359:741-6
   PubMed Web of Science ®Google Scholar
• Webster AC, Woodroffe RC, Taylor RS, Tacrolimus versus ciclosporin as primary immunousppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trials. BMJ 2005;331:810-21
   PubMed Web of Science ®Google Scholar
• Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-95
   PubMed Web of Science ®Google Scholar
• Marks WH, Harding MW, Hanschumacher R, The immunochemical distribution of cyclophilin in normal mammalian tissues. Transplantation 1991;52:340-5
   Google Scholar
• Tamura K, Fujimura T, Tsutsumi T, Transcitional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995;59:1606-13
   PubMed Web of Science ®Google Scholar
• Øzbay LA, Smidt K, Mortensen DM, Cyclosporin and tacrolimus impair insulin secretion and transcriptional reglation in INS-1E beta-cells. Br J Pharmacol 2011;162:136-46
   PubMed Web of Science ®Google Scholar
• Redmon JB, Olson LK, Armstrong MB, Effects of Tacrolimus [FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98:2786-93
   PubMed Web of Science ®Google Scholar
• Boots JMM, van Duijnhoven EM, Christiaans MHL, Glucose metabolism in renal transplant receipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002;13:221-7
   PubMed Web of Science ®Google Scholar
• Dumortier J, Bernard S, Bouffard Y, Biollo O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006;12:659-64
   Google Scholar
• Bloom RD, Rao V, Weng F, Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374-80
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Jenssen T, Hatmann A, No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant 2011. [Epub ahead of print]
   Google Scholar
• Asberg A, Midtvedt K, Line PD, Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006;82:62-8
   PubMed Web of Science ®Google Scholar
• Di Paolo S, Teutonico A, Leogrande D, Chronic inhibition of mammalian target of rapamycin signaling down-regulates insulin receptor substrates 1 and 2 and AKT activiation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236-44
   PubMed Web of Science ®Google Scholar
• Fraenkel M, Ketzinel-Gilad M, Ariav Y, mTor inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57
   PubMed Web of Science ®Google Scholar
• Kreis H, Cisterne JM, Land W, Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60
   PubMed Web of Science ®Google Scholar
• MacDonald AS; The Rapamune global study group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80
   PubMed Web of Science ®Google Scholar
• Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35
   PubMed Web of Science ®Google Scholar
• Romagnoli J, Citterio F, Nanni G, Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006;38:1034-6
   PubMed Web of Science ®Google Scholar
• Morrisett JD, Abdel-Fattah G, Hoogeveen R, Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002;43:1170-80
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose CL, Webster AC, Gill JC. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Mari A, Tura A, Natali A, Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia 2010;53:749-56
   PubMedGoogle Scholar
• Bergrem H, Gretland Valderhaug T, Hartmann A, Undiagnosed diabetes in kidney transplant candidates: a case-finding study. Clin J Am Soc Nephrol 2010;5:616-22
   PubMed Web of Science ®Google Scholar
• Zelle DM, Corpeleijn E, Stolk RP. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011;6:898-905
   PubMed Web of Science ®Google Scholar
• Valderhaug TG, Jenssen T, Hartmann A, Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009;88:429-34
   PubMed Web of Science ®Google Scholar
• Zerr KJ, Furnary AP, Grunkenmeier GL, Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997;63:356-61
   PubMed Web of Science ®Google Scholar
• Furnary AP, Gao G, Grunkenmeier GL, Continuous insulin infusion reduces mortality in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125:1007-21
   PubMed Web of Science ®Google Scholar
• Van Den Berghe G, Wilmer A, Hermans G, Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61
   PubMed Web of Science ®Google Scholar
• Clement S, Braithwaite SS, Magee MF, Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553-91 Erratum in Diabetes Care 2004;27856. Diabetes Care 2004;27:1255
   PubMed Web of Science ®Google Scholar
• Qseem A, Humphrey LL, Chou R, Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;154:260-7
   Google Scholar
• Nathan DM, Buse JB, Davdidson MB, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, Intensive treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34:S11-61
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• KDIGO. Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009;9(Suppl 3):S66-80
   Google Scholar
• Identification number: NCT01304836 Available from: www.clinicaltrials.gov
   Google Scholar
• Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008;14:979-84
   PubMedGoogle Scholar
• Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24:1160-3
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:145-54
   Google Scholar
• Zoungas S, Patel A, Chalmers J, Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-18
   PubMed Web of Science ®Google Scholar
• Sagedal S, Asberg A, Hartmann A, Glipizide treatment of posttransplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Clin Transplant 1998;12:553-6
   Google Scholar
• Turk TR, Pietruck F, Dolff S, Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006;6:842-6
   PubMed Web of Science ®Google Scholar
• Voytovich MH, Haukereid C, Hjelmesaeth J, Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin Transplant 2007;21:246-51
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niewmi M, Neuvonen M, Cyclosporine markedly raises the plasma concentration of repaglinide. Clin Pharmacol Ther 2005;78:388-99
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care 2008;31:845-51
   PubMed Web of Science ®Google Scholar
• Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135-8
   PubMed Web of Science ®Google Scholar
• Voytovich MH, Simonsen C, Jenssen T, Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005;20:413-18
   Google Scholar
• Pinelli NR, Moore CL, Tomasello S. Incretin-based therapy in chronic kidney disease. Adv Chronic Kidney Dis 2010;17:439-49
   Google Scholar
• Pirelli NR, Nemerovski CW, Koelling TM. Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. Transplant Proc 2011;43:2113-15
   Google Scholar
• Haidinger M, Werzowa J, Voigt HC, A randomized, placebo-controlled, double-blind trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 2010;11:91
   Google Scholar
• Identification number: NCT00740363 Available from: www.clinicaltrials.gov
   Google Scholar
• Chan JC, Scott R, Ariona Ferreira JC, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellstrom B, Jardine AG, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31
   PubMed Web of Science ®Google Scholar